{"generic":"Rifaximin","drugs":["Rifaximin","Xifaxan"],"mono":{"0":{"id":"928167-s-0","title":"Generic Names","mono":"Rifaximin"},"1":{"id":"928167-s-1","title":"Dosing and Indications","sub":[{"id":"928167-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hepatic encephalopathy; Prophylaxis:<\/b> 550 mg ORALLY twice daily<\/li><li><b>Irritable bowel syndrome with diarrhea:<\/b> 550 mg ORALLY 3 times daily for 14 days; may repeat up to 2 times with the same dosage regimen<\/li><li><b>Traveler's diarrhea, Noninvasive strains of E coli:<\/b> 200 mg ORALLY 3 times daily for 3 days<\/li><\/ul>"},{"id":"928167-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy have not been established in pediatric patients for the treatment of hepatic encephalopathy or irritable bowel syndrome with diarrhea.<\/li><li><b>Traveler's diarrhea, Noninvasive strains of E coli:<\/b> (12 years or older) 200 mg ORALLY 3 times daily for 3 days<\/li><\/ul>"},{"id":"928167-s-1-6","title":"Dose Adjustments","mono":"<b>Hepatic impairment:<\/b> No adjustment necessary "},{"id":"928167-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hepatic encephalopathy; Prophylaxis<\/li><li>Irritable bowel syndrome with diarrhea<\/li><li>Traveler's diarrhea, Noninvasive strains of E coli<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Crohn's disease<\/li><li>Hepatic encephalopathy<\/li><\/ul>"}]},"3":{"id":"928167-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928167-s-3-9","title":"Contraindications","mono":"hypersensitivity to rifaximin, any component of the product, or other rifamycin antimicrobial agents <br\/>"},{"id":"928167-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- Clostridium difficile-associated diarrhea (CDAD) has been reported; discontinue if suspected or confirmed<\/li><li>-- avoid use in diarrhea complicated by fever or blood in the stool, or due to pathogens other than Escherichia coli<\/li><li>Hepatic:<\/li><li>-- severe hepatic impairment (Child-Pugh C); caution advised due to increased systemic exposure<\/li><li>Immunologic:<\/li><li>-- anaphylaxis, angioneurotic edema, and exfoliative dermatitis have been reported<\/li><\/ul>"},{"id":"928167-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"928167-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928167-s-4","title":"Drug Interactions","sub":{"1":{"id":"928167-s-4-14","title":"Major","mono":"<ul><li>Eliglustat (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><\/ul>"}}},"5":{"id":"928167-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (15%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (9%), Nausea (2% to 14%)<\/li><li><b>Hepatic:<\/b>Ascites (11%)<\/li><li><b>Neurologic:<\/b>Dizziness (13%), Headache (10%)<\/li><li><b>Other:<\/b>Fatigue (12%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Anemia (8%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"928167-s-6","title":"Drug Name Info","sub":{"0":{"id":"928167-s-6-17","title":"US Trade Names","mono":"Xifaxan<br\/>"},"2":{"id":"928167-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Rifamycin<\/li><\/ul>"},"3":{"id":"928167-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928167-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928167-s-7","title":"Mechanism Of Action","mono":"Rifaximin is a semi-synthetic, non-systemic antibiotic that inhibits bacterial RNA synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase.<br\/>"},"8":{"id":"928167-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"928167-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1 hour<\/li><li>Bioavailability, Oral: limited systemic exposure<\/li><li>Effects of food: increased systemic exposure (2-fold increase in AUC)<\/li><\/ul>"},"1":{"id":"928167-s-8-24","title":"Distribution","mono":"Protein binding: 62% to 67.5% <br\/>"},"3":{"id":"928167-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 96.62% (almost entirely as unchanged drug)<\/li><li>Renal: 0.32%; 0.03% unchanged<\/li><\/ul>"},"4":{"id":"928167-s-8-27","title":"Elimination Half Life","mono":" 6 hours (irritable bowel syndrome with diarrhea) <br\/>"}}},"9":{"id":"928167-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>May be taken with or without food <br\/>"},"10":{"id":"928167-s-10","title":"Monitoring","mono":"improved diarrhea, hydration level<br\/>"},"11":{"id":"928167-s-11","title":"How Supplied","mono":"<b>Xifaxan<\/b><br\/>Oral Tablet: 200 MG, 550 MG<br\/>"},"12":{"id":"928167-s-12","title":"Toxicology","sub":[{"id":"928167-s-12-31","title":"Clinical Effects","mono":"<b> RIFAXIMIN <\/b><br\/>OVERDOSE: Overdose information are limited. Effects reported at doses greater than 600 mg\/day have been similar to those reported with therapeutic use. ADVERSE EFFECTS: The most common adverse effects (greater than or equal to 2%) are flatulence, headache, abdominal pain, rectal tenesmus, defecation urgency, nausea, vomiting, constipation and fever. However, these effects may be caused by underlying disease. Other reported adverse effects include allergic dermatitis, rash, urticaria, pruritus, weight loss, abdominal distension, diarrhea, dry throat, gingival disorder, inguinal hernia, dry lips, blood in stool, hematuria, choluria, dysuria, polyuria, proteinuria, urinary frequency, lymphocytosis, monocytosis, neutropenia, tinnitus, increases in aspartate aminotransferase, arthralgia, muscle spasms, myalgia, neck pain, headache, motion sickness, fatigue, malaise, abnormal dreams, dizziness, migraine, insomnia, syncope, loss of taste, respiratory tract infections, dyspnea, nasal passage irritation, nasopharyngitis, pharyngitis, pharyngolaryngeal pain, rhinitis and rhinorrhea.<br\/>"},{"id":"928167-s-12-32","title":"Treatment","mono":"<b> RIFAXIMIN <\/b><br\/><ul><li>Decontamination: Rifaximin undergoes minimal absorption from the gastrointestinal tract with a bioavailability of less than 0.4%. GI decontamination is generally not indicated.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Monitor CBC, renal function and hepatic enzymes, and fluid and electrolyte status in symptomatic patients.<\/li><li>Enhanced elimination procedure: There is no information regarding the effectiveness of hemodialysis or hemoperfusion for the removal of rifaximin from plasma. Since systemic absorption is minimal, with a bioavailability of less than 0.4%, methods to enhance systemic elimination are unlikely to be necessary.<\/li><\/ul>"},{"id":"928167-s-12-33","title":"Range of Toxicity","mono":"<b> RIFAXIMIN <\/b><br\/>TOXICITY: Overdose information is limited. Following the administration of doses higher than the recommended dose of 600 mg\/day, adverse effects were similar to those observed at the recommended dose. THERAPEUTIC: Patients 12 years of age or older - 200 mg tablet three times daily for 3 days. <br\/>"}]},"13":{"id":"928167-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>This drug may cause headache, fatigue, ascites, peripheral edema, muscle spasms, pruritus, flatulence, nausea, or abdominal pain.<\/li><li>Instruct patient with traveler's diarrhea to report fever, bloody diarrhea, or diarrhea that worsens or persists after 1 to 2 days of therapy.<\/li><li>Instruct patient with hepatic encephalopathy to immediately report signs\/symptoms of Clostridium difficile-associated diarrhea (watery or bloody diarrhea, with or without fever) during or after discontinuation.<\/li><\/ul>"}}}